Russia developing hepatitis B gene therapy

Sechenov University of Russia, in collaboration with R-Pharm Pharmaceuticals, has begun developing a new drug targeting hepatitis B virus using CRISPR-Cas9 gene editing technology. The project aims to provide an effective treatment for the disease and is now in advanced stages of research and development after receiving a grant named after Academician E. P. Vilekhov.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل